Hepatitis B is an inflammatory condition that occurs due to
infection by hepatitis B virus. Hepatitis B virus is an enveloped virus that
belongs to the family of hepadnavirus. It contains a circular genome with
partially double-stranded DNA. The virus interferes with the normal functioning
of the liver cells. Following the viral infection, the immune system is
activated against virus and hepatocytes infected with viruses. This, in turn,
leads to the inflammation of the liver. Extra-hepatic manifestations of
hepatitis B include polyarteritis nodosa, Gianotti-Crosti syndrome, transient
serum sickness-like syndrome, and membranous glomerulonephritis. Perinatal
transmission of hepatitis B virus is the most common mode of infection spread.
Age of a person at the time of infection and infecting dose of virus are
important factors that determine the severity of acute or chronic hepatitis B.
Most of the patients suffering from acute hepatitis B recover spontaneously
without significant consequences. The chronic form of infection, in some cases,
can progress up to cirrhosis and liver cancer. Hepatitis B infection can be
prevented by immunization with hepatitis B vaccines.
Analysts forecast the Global Hepatitis B Vaccines market to
grow at a CAGR of 4.00 percent over the period 2013-2018.
The Report recognizes the following companies as the key
players in the Global Hepatitis B Vaccines Market: GlaxoSmithKline plc, Merck
& Co. Inc. and Sanofi Pasteur SA
Other Prominent Vendors in the market are: Dynavax
Technologies, Janssen Pharmaceuticals, Kaketsuken, LG Life Sciences and
Shenzhen Kangtai Biological Products
Inquire on the Report
at http://www.sandlerresearch.org/inquire-before-buying?rname=22742 .
Covered in this Report
This report covers the present scenario and the growth
prospects of the Global Hepatitis B Vaccines market for the period 2014-2018.
To calculate the market size, the report considers revenue generated through
the sales of various vaccines intended for active immunization against
different serogroups of hepatitis B virus. In terms of composition, the Global
Hepatitis B Vaccines market can be segmented into the following: Mono Vaccines
and Combination Vaccines.
Global Hepatitis B Vaccines Market 2014-2018, has been
prepared based on an in-depth market analysis with inputs from industry
experts. The report covers the Americas, and the APAC and EMEA regions; it also
covers the Global Hepatitis B Vaccines market landscape and its growth
prospects in the coming years. The report includes a discussion of the key
vendors operating in this market.
One of the key emerging trends in this market is the
increasing focus on combination vaccines. These vaccines confer protection
against multiple causative agents and thereby decrease the costs incurred in
packaging and administering individual vaccines.
According to the report, recommendation of hepatitis B
vaccines while traveling is one of the major drivers in the market. Various
government bodies have mandated the immunization of travelers visiting
hepatitis B-prone areas with prophylactic vaccines for the prevention of the
spread of infection and reduction in the chance of epidemic outbreaks.
Further, the report states that inadequate coverage of the
vaccine is one of the major challenges in the market. Lack of awareness is a
major factor limiting the uptake of vaccines, resulting in low coverage rates.
Get discount on the
Report at http://www.sandlerresearch.org/discount?rname=22742 .
